(Q61969984)

English

Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. (English)

0 references

0 references

0 references

0 references

0 references

February 2015

0 references

end time

December 2015

0 references

number of participants

1,560

0 references

clinical trial phase

phase III clinical trial

0 references

research subject recruitment status

completed

0 references

minimum age

12 month

0 references

maximum age

18 month

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT01991899

0 references

(Q61969984)

Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)